Following on from @Titan19 &
@LongTony comments above, a timely reminder for rusted-on longs and newbies alike, of the potential value of bisantrene in the AML market.
From RAC’s investor presentation November 2021
https://www.raceoncology.com/wp-content/uploads/2021/12/Investor-Presentation-November-2021.pdf
estimated annual revenue for treatment of AML with bisantrene is ~$USD 300M
Potential value
3.5 x sales = $USD 1.05 bill = $AUD 1.567 bill = $8.95/share (assume 175M SOI)
4.0 x sales =$USD 1.2 bill = $AUD 1.791 bill = $10.23/share“
5.0 x sales =$USD 1.5 bill = $AUD 2.223 bill = $12.79/share“
So just for AMLalone, IMHO, the potential value is in therange of $8.95 - $12.79per share
(20min delay)